Warrants - Summary of continuity schedule (Details) - $ / shares |
12 Months Ended | |
|---|---|---|
Mar. 31, 2023 |
Mar. 31, 2022 |
|
| Warrants | ||
| Number of Warrants, Outstanding and exercisable, beginning balance | 79,683 | 122,367 |
| Weighted Average Exercise Price, Outstanding and exercisable, beginning balance | $ 25.22 | $ 19.69 |
| Number of Warrants, Expired | (79,683) | (42,684) |
| Weighted Average Exercise Price, Expired | $ (25.22) | $ (9.38) |
| Number of Warrants, Granted | 400,000 | |
| Weighted Average Exercise Price, Granted | $ 0.40 | |
| Number of Warrants, Outstanding and exercisable, ending balance | 400,000 | 79,683 |
| Weighted Average Exercise Price, Outstanding and exercisable, ending balance | $ 0.40 | $ 25.22 |
| X | ||||||||||
- Definition Weighted average exercise price of non options exercised during the period. No definition available.
|
| X | ||||||||||
- Definition Weighted average exercise price of non options exercised during the period. No definition available.
|
| X | ||||||||||
- Definition Number of shares under non-option equity instrument agreements for which rights to exercise lapsed. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References No definition available.
|